178 related articles for article (PubMed ID: 28154895)
1. Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
Zhang X; Pan J
Ann Hematol; 2017 Apr; 96(4):707-708. PubMed ID: 28154895
[No Abstract] [Full Text] [Related]
2. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
3. Resistance to therapy in acute promyelocytic leukemia.
Lehmann-Che J; Bally C; de Thé H
N Engl J Med; 2014 Sep; 371(12):1170-2. PubMed ID: 25229938
[No Abstract] [Full Text] [Related]
4. Current treatment of acute promyelocytic leukemia.
Lo Coco F; Ammatuna E; Sanz MA
Haematologica; 2007 Mar; 92(3):289-91. PubMed ID: 17339175
[No Abstract] [Full Text] [Related]
5. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
Strehl S; König M; Boztug H; Cooper BW; Suzukawa K; Zhang SJ; Chen HY; Attarbaschi A; Dworzak MN
Leukemia; 2013 Jul; 27(7):1606-10. PubMed ID: 23271512
[No Abstract] [Full Text] [Related]
6. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
7. [Treatment for acute promyelocytic leukemia].
Fujita H
Rinsho Ketsueki; 2014 Oct; 55(10):1817-26. PubMed ID: 25297745
[No Abstract] [Full Text] [Related]
8. All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.
Tallman MS
Leuk Lymphoma; 2010 May; 51(5):745-6. PubMed ID: 20423285
[No Abstract] [Full Text] [Related]
9. Complete remission of acute promyelocytic leukemia in a very elderly patient after treatment with low dose arsenic trioxide and sequential retinoic acid: a case report.
Lin J; Zhu H; Li S; Fan H; Lu X
Ann Hematol; 2014 Feb; 93(2):335-6. PubMed ID: 23719691
[No Abstract] [Full Text] [Related]
10. Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
Visani G; Piccaluga PP; Martinelli G; Rossi M; Malagola M; Baccarani M
Haematologica; 2003 Apr; 88(4):ELT15. PubMed ID: 12681992
[No Abstract] [Full Text] [Related]
11. Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid.
Breccia M; Molica M; Efficace F; Minotti C; Latagliata R; Foà R; Lo Coco F
Br J Haematol; 2014 Nov; 167(3):428-30. PubMed ID: 24957334
[No Abstract] [Full Text] [Related]
12. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
13. [All-trans retinoic acid and arsenic trioxide: their molecular mechanisms of action and updated clinical progress in APL therapy].
Shinagawa K
Rinsho Ketsueki; 2011 Jul; 52(7):469-83. PubMed ID: 21821978
[No Abstract] [Full Text] [Related]
14. How I treat acute promyelocytic leukemia.
Tallman MS; Altman JK
Blood; 2009 Dec; 114(25):5126-35. PubMed ID: 19797519
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Breccia M; Cicconi L; Minotti C; Latagliata R; Giannì L; Lo-Coco F
Haematologica; 2011 Sep; 96(9):1390-1. PubMed ID: 21659361
[No Abstract] [Full Text] [Related]
16. Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
Gao N; Wang XX; Sun JR; Yu WZ; Li XZ
Ann Hematol; 2017 May; 96(5):711-718. PubMed ID: 28238096
[TBL] [Abstract][Full Text] [Related]
17. [Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia].
Zhang GC; Zheng D; Li QH; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Apr; 23(4):430-4. PubMed ID: 15087033
[TBL] [Abstract][Full Text] [Related]
18. Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients.
Malhotra P; Varma N; Arora N; Das R; Nath A; Patel FD; Varma S
Leuk Lymphoma; 2010 May; 51(5):933-6. PubMed ID: 20350274
[No Abstract] [Full Text] [Related]
19. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?
Lallemand-Breitenbach V; de Thé H
Blood; 2013 Sep; 122(12):2008-10. PubMed ID: 23894153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
